STAT Plus: Crash and burn: The four biggest biopharma failures of 2019
ALEX HOGAN/STAT
We looked back at the four most significant biopharma blowups of the year — and the consequences they had for patients, investors and employees.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario